Company profile
Alto Neuroscience, Inc.
NYSE:ANROBiotechnology: Pharmaceutical Preparations
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06656416 | phase2 | recruiting | 2024-10-02 | 2026-08-01 | Alto Neuroscience | ALTO-100 in Bipolar Disorder With Depression (BD-D) |
| NCT05117632 | phase2 | completed | 2021-12-20 | 2022-12-01 | Alto Neuroscience | ALTO-100 in MDD and/or PTSD |
| NCT07553637 | phase2 | recruiting | 2026-05-01 | 2027-11-01 | Alto Neuroscience | ALTO-207 in Adults With Treatment-resistant Depression (TRD) |
| NCT05118750 | phase2 | completed | 2021-12-13 | 2023-05-05 | Alto Neuroscience | ALTO-300 in Depression |
| NCT05157945 | phase2 | completed | 2022-02-03 | 2023-04-26 | Alto Neuroscience | ALTO-300 in Depression (ALTO-300-004) |
FDA applications (0)
No records yet.